Rosnilimab Emerges As A Potential Advance In Rheumatoid Arthritis As Physicians Look To The Next Wave Of Pipeline Innovation

(MENAFN- GlobeNewsWire - Nasdaq) New Spherix Global Insights research finds rheumatologists estimate 16% of rheumatoid arthritis patients are refractory to treatment, underscoring continued demand for differentiated therapies despite an increasingly crowded market.

Exton, PA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- As the Rheumatoid Arthritis (RA) treatment landscape becomes increasingly competitive, rheumatologists are looking to the pipeline for therapies that can offer more than incremental differentiation. New research from Spherix Global Insights finds particularly strong enthusiasm for First Tracks Biotherapeutics' rosnilimab, which physicians are increasingly viewing as a potentially meaningful advance over currently available treatments.

Findings from Spherix Global Insights' refresh of Market DynamixTM: Rheumatoid Arthritis (US) 2026, based on a survey of 103 U.S. rheumatologists conducted July 30 through August 5, show physician interest spanning differentiated approaches to immune modulation, led by First Tracks Biotherapeutics' PD-1 agonist rosnilimab and Immunovant's FcRn inhibitor imeroprubart (IMVT-1402). At the same time, the research highlights persistent unmet need among patients with refractory or difficult-to-treat RA despite the breadth of therapies already available.

Rosnilimab Stands Out as a Potential Advance in the RA Pipeline

Rosnilimab differentiates itself not only through its novel mechanism, but also through rheumatologists' assessment of its potential clinical value. Nearly one-third of physicians rate the agent as a substantial advance over current RA treatment options, the highest proportion among the pipeline therapies evaluated. Physicians point to its efficacy, durability, and safety profile as key reasons for enthusiasm.

The findings suggest that novelty alone is not enough to break through in a mature RA market. Rheumatologists appear to be rewarding programs that combine a differentiated mechanism with evidence that could translate into meaningful improvements in efficacy, durability, or safety.

The research also illustrates that meaningful innovation does not necessarily require an entirely new therapeutic target. Sanofi's oral TNF inhibitor balinatunfib (SAR441566) generated strong physician interest in the study, with rheumatologists citing both the familiarity of TNF inhibition and the convenience of oral administration as key sources of appeal. Sanofi announced the discontinuation of the balinatunfib clinical development program on July 30, as Spherix's research was in the field. While the asset is no longer advancing, physician response to its profile highlights continued interest in treatment approaches that combine established mechanisms with meaningful improvements in convenience.

Difficult-to-Treat RA Reinforces the Need for New Treatment Approaches

The need for continued innovation is particularly evident among patients with difficult-to-treat (D2T) or refractory RA, where physicians may cycle through multiple mechanisms without achieving adequate disease control. Rheumatologists estimate that 16% of their RA patients are refractory to treatment, a meaningful population given the breadth of advanced therapies already available.

Spherix's qualitative research suggests rheumatologists distinguish refractory RA, generally characterized by failure of multiple biologic or targeted therapy classes, from the broader D2T population. Difficult-to-treat patients may include those with refractory disease, but also patients whose management is complicated by comorbidities, treatment intolerances, psychosocial or access barriers, and overlapping pain syndromes such as fibromyalgia.

For these patients, physicians describe treatment journeys that can span TNF inhibitors, JAK inhibitors, IL-6 inhibitors, T-cell modulation, and B-cell-directed therapy, underscoring the limitations of simply cycling through existing options.

This challenge may also help explain physician interest in emerging mechanisms. Immunovant's IMVT-1402 (imeroprubart), an investigational FcRn inhibitor being studied specifically in difficult-to-treat RA patients who have failed at least two prior advanced therapies, offers a non-depleting approach designed to reduce circulating IgG, including pathogenic RA autoantibodies, representing another potential avenue for patients who have exhausted multiple existing mechanisms. Physician perceptions reflect that potential, with imeroprubart ranking alongside rosnilimab among the pipeline agents viewed most favorably as potential advances over current treatment.

Biosimilars and Rinvoq Continue to Reshape the Current RA Market

Pipeline innovation is emerging against a backdrop of measured change in the established treatment market. Biologics and JAK inhibitors now account for the majority of RA treatment, and rheumatologists expect their use to increase further over the next six months.

Within advanced therapies, the long-standing dominance of branded TNF inhibitors continues to erode. Adalimumab biosimilars have overtaken AbbVie's Humira (adalimumab) in the first-line setting, while legacy branded TNF inhibitors continue to face share pressure. Alternative mechanisms are also gaining ground, particularly AbbVie's Rinvoq (upadacitinib), which shows strong near-term momentum and is used increasingly as patients move into later lines of therapy.

These shifts underscore an increasingly demanding environment for future entrants. New RA therapies will compete not only with established biologics and JAK inhibitors, but with lower-cost biosimilars and increasingly entrenched alternative mechanisms.

Generic Tofacitinib Creates New Pressure on Xeljanz-but Limited Spillover So Far

The arrival of generic tofacitinib is introducing another layer of competition, although Spherix research suggests its near-term impact is likely to remain concentrated primarily on Pfizer's Xeljanz (tofacitinib).

More than half of physicians expect generic tofacitinib to have a substantial impact on Xeljanz use. By comparison, just one-fifth anticipate a substantial impact on Rinvoq, while biologic competitors are expected to see relatively little effect.

The findings point to an important distinction in the evolving RA market: cost-driven disruption is intensifying within established classes, but physicians continue to reserve their strongest enthusiasm for pipeline therapies that offer a clearly differentiated clinical or treatment proposition.

RA Innovation Faces a Higher Bar for Differentiation

Taken together, the 2026 Market Refresh reveals a market changing from both directions. Biosimilars and generics are increasing price and access pressure on legacy brands, while newer established therapies continue to gain ground based on physician preference and clinical positioning. At the same time, the persistent challenge of difficult-to-treat RA highlights the limits of today's treatment arsenal. That need persists amid relatively limited physician satisfaction with the current treatment landscape: just half of rheumatologists say they are satisfied with available RA treatment options.

Against that backdrop, the early enthusiasm surrounding First Tracks Biotherapeutics' rosnilimab and physician attention to emerging approaches such as Immunovant's imeroprubart suggest rheumatologists still see meaningful room for innovation in RA-but differentiation will need to be tangible.

For developers entering the next phase of the RA market, the opportunity may therefore lie less in simply adding another effective therapy and more in delivering a meaningful advance in efficacy, durability, safety, mechanism, or treatment convenience-particularly for patients who remain inadequately served by existing options.

Market DynamixTM: Rheumatoid Arthritis (US) 2026 provides an updated assessment of the U.S. RA treatment landscape, including current and anticipated treatment utilization, payer dynamics, generic tofacitinib adoption, difficult-to-treat RA, unmet needs, clinical trial expectations, and rheumatologist perceptions of emerging pipeline therapies.

About Market DynamixTM

Market DynamixTM is an independent service that provides an in-depth analysis of markets anticipated to experience a paradigm shift within the next three to five years. The service examines market size, current treatment approaches, unmet needs, and physician perspectives on the potential impact of emerging therapies.

About Spherix Global Insights

Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into a single integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it. The firm operates ten dedicated therapeutic franchises – Cardiovascular Kidney Metabolic Disease (CKM), Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Oncology, Ophthalmology, Respiratory and Rheumatology – alongside a fully dedicated Market Access team. Each franchise is led by hyper-focused analysts and researchers who track these specialty areas full-time, drawing on independently curated communities of vetted practicing specialists, KOLs, patients recruited through treating physicians and advocacy partners, and medical and pharmacy directors at commercial and government payers. Spherix delivers quarterly trending, launch tracking, chart audits, KOL synthesis, patient experience research, and payer and market access intelligence that support confident, strategic decision-making across the pharma lifecycle. Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, market access stakeholders, industry media outlets, financial analysts, professional organizations, and patient advocacy groups seeking an unbiased, holistic view of specialty markets.

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.

For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: .

NOTICE: All company, brand, or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insights' analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.

CONTACT: Lynn Price Spherix Global Insights 484-879-4284...

MENAFN10092026004107003653ID1111647177